Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Libtayo Inf |
|---|---|
| Manufacturer | Sanofi-Aventis Deutschland GmbH |
| Prescription required | Yes |
Libtayo Inf 350mg 1ST x 7ml(Cemiplimab)
Cemiplimab
Description
Libtayo Inf 350mg 1ST x 7ml(Cemiplimab) is a medicine catalog record in the MediPriceHub database. Active ingredient: Cemiplimab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Sanofi-Aventis Deutschland GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Skin Cancer Medicines. Pack information: 350 / 7. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Non-Small Cell Lung Cancer (NSCLC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic.How to Use
Use Cemiplimab under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Cemiplimab. Pack size: 350 / 7. Pack unit: bottle. Manufacturer: Sanofi-Aventis Deutschland GmbH. Origin country: Switzerland. Source category: Medicine Library > Oncology Medicines > Skin Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.This information is for reference only. Consult a qualified healthcare professional before using any medicine.